title: ACS chemical neuroscience molecule spotlight on Suvorexant.
abstract: Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.
authors.affiliation: Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology and Chemistry, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, USA.
authors.forename: Corey R
authors.initials: CR
authors.lastname: Hopkins
mesh_terms: D000818:Animals; D001381:Azepines / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology* / Q000627:therapeutic use; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D009479:Neuropeptides / Q000037:antagonists & inhibitors / Q000502:physiology; D000068797:Orexins; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D014230:Triazoles / Q000494:pharmacology* / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000502:physiology
chemical_list: D001381:Azepines; D006993:Hypnotics and Sedatives; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D014230:Triazoles; C551624:suvorexant; D005680:gamma-Aminobutyric Acid